


Supplementary Figure 6



Supplementary Figure 6: Comparison of MAC-Score and BH3-profiling based response prediction

A-M Comparison of MAC-Score and BH3-profiling in a selected subset of 5-AZA/VEN first-line AML patient samples from cohorts 1, 2 and 3 (N = 15).

A MAC-Score in *LSC-like* cells with 5-AZA/VEN therapy outcome.

B-C Event-free survival of first-line 5-AZA/VEN AML patients stratified by above and below **B** median MAC-Scores of the selected samples or **C** previously defined 0.4 cut-off.

D-G BH3-profiling results plotted as 5-AZA/VEN therapy outcome with AUC of cytochrome C release in *LSC-like* cells mediated by **D** VEN, **E** HRK, **F** MS1 and **G** combination of HRK and MS1.

H Event-free survival of first-line 5-AZA/VEN AML patients stratified by above and below median of VEN AUC in *LSC-like* cells.

I-L BH3-profiling results plotted as 5-AZA/VEN therapy outcome with AUC of cytochrome C release in total blast cells mediated by **I** VEN, **J** HRK, **K** MS1 and **L** combination of HRK and MS1.

M Event-free survival of first-line 5-AZA/VEN AML patients stratified by above and below median of VEN AUC in total blast cells.

Each dot represents an AML patient sample with the line marking the mean unless specified otherwise. Mann-Whitney test was used to compare groups. LSC: Leukemic stem cell, MAC-Score: Mediators of Apoptosis Combinatorial Score, 5-AZA: Azacitidine, VEN: Venetoclax